Shelley E. Crary
Professor, Pediatric Hematology-Oncology
University of Arkansas for Medical Sciences
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Shelley E. Crary, Professor of Pediatrics in the Division of Pediatric Hematology-Oncology at the University of Arkansas for Medical Sciences (UAMS), focuses her research on hematological disorders in children. She serves as the Medical Director of the Arkansas Center for Bleeding Disorders and the Director of Hematology at Arkansas Children’s Hospital (ACH). Her work includes investigating treatment practices and responses in conditions such as kaposiform hemangioendothelioma and exploring the pharmacokinetics of treatments like bleomycin sclerotherapy for vascular malformations.
Dr. Crary's research also extends to venous thromboembolism in pediatric patients, examining the effects of anticoagulant therapy duration on recurrence and bleeding events. She has published on the long-term biological effects in sickle cell disease and contributes to defining pediatric refractory immune thrombocytopenia (ITP). Her publications reflect a commitment to understanding and improving care for children with complex blood disorders, including gene therapy for conditions like Hemophilia B.
Beyond clinical research, Dr. Crary is dedicated to advancing translational science and fostering career development in the field. She is Co-Director of the UAMS Clinical and Translational Science Pilot Program and the UAMS Master’s in Clinical and Translational Sciences Scholarship Program, mentoring junior faculty and fellows. She is also an inaugural mentor in the American Society of Hematology (ASH) Classical Hematology Mentorship Program, underscoring her commitment to education and research training.
Metrics
- h-index: 20
- Publications: 100
- Citations: 1,883
Selected Publications
- Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study (2025) DOI
- Multimodal neuroimaging and neurocognitive assessment in adolescents with and without sickle cell disease (2025) DOI
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children (2025) DOI
- Knowledge, interest, and willingness of hematologists and oncologists to care for adults with vascular anomalies (2025) DOI
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment (2025) DOI
- Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease (2025) DOI
- Pediatric hematology: selected topics (2025) DOI
- Hemostasis and thrombosis risks and management in vascular anomalies (2024) DOI
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children (2024) DOI
- Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes (2024) DOI
- What is in a name: defining pediatric refractory ITP (2024) DOI
- A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders (2024) DOI
- Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study (2023) DOI
- Safety and Pharmacokinetics of Recombinant ADAMTS13 in Patients with Sickle Cell Disease: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study (2023) DOI
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update (2023) DOI
Grants & Funding
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics